AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12791113 — intervention group
Group type: COMPARATOR
Intervention: 0.7 ml.kg-1, 1.0 ml.kg-1, 1.3 ml.kg-1 of 0.175% bupivacaine with 1 : 200 000 epinephrine
Number of subjects: 54
Study 10739792 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 9
Study 9376887 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 354
Study 9376887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 1398281 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg intramuscularly twice a day starting the day before surgery)
Number of subjects: 81
Study 1398281 — intervention group
Group type: COMPARATOR
Intervention: Calcium Heparin (5000 IU subcutaneously twice daily beginning 2 hours before surgery)
Number of subjects: 81
Study 1398281 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 81
Study 1398281 — intervention group
Group type: COMPARATOR
Intervention: Calcium Heparin
Number of subjects: 81
Study 3912189 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindeburnol 30, 60 or 90 mg/d
Number of subjects: 0
Study 3912189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31103981 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermocosmetic emulgels loaded with Diospyros kaki fruit extract (DKFE)
Number of subjects: 0
Study 31103981 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 27888448 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clobetasol propionate 0.05% cream under occlusion with silicone dressing
Number of subjects: 17
Study 27888448 — intervention group
Group type: COMPARATOR
Intervention: Intra-lesional triamcinolone
Number of subjects: 17
Study 26409701 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional Release Therapy (PRT) combined with routine medical therapy
Number of subjects: 44
Study 26409701 — intervention group
Group type: COMPARATOR
Intervention: Routine medical therapy alone
Number of subjects: 44
Study 24010644 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-0938 for 14 days
Number of subjects: 40
Study 24010644 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-0938 for 7 days followed by GS-0938 plus sofosbuvir for 7 days
Number of subjects: 40
Study 24010644 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir for 7 days followed by GS-0938 plus sofosbuvir for 7 days
Number of subjects: 40
Study 24010644 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-0938 plus sofosbuvir for 14 days
Number of subjects: 40
Study 24010644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21213171 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeing oneself on screen (exergame feature)
Number of subjects: 0
Study 21213171 — intervention group
Group type: EXPERIMENTAL
Intervention: Not seeing oneself on screen (exergame feature)
Number of subjects: 0
Study 18005082 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) in addition to transplanted bone
Number of subjects: 53
Study 18005082 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 53
Study 16799234 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg edaravone intravenously just before reperfusion
Number of subjects: 101
Study 16799234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 13679933 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (30‐ to 45‐second delay in cord clamping)
Number of subjects: 32
Study 13679933 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 32
Study 11125896 — intervention group
Group type: EXPERIMENTAL
Intervention: Health worker training and STD syndrome packets (containing recommended drugs, condoms, partner notification cards, and information leaflets)
Number of subjects: 0
Study 11125896 — intervention group
Group type: EXPERIMENTAL
Intervention: Health worker training and STD syndrome packets
Number of subjects: 0
Study 11125896 — intervention group
Group type: COMPARATOR
Intervention: Routine syndromic management (control)
Number of subjects: 0
Study 9136151 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizing lotion
Number of subjects: 22
Study 9136151 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 22
Study 1401622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase, 150,000 U
Number of subjects: 93
Study 1401622 — intervention group
Group type: COMPARATOR
Intervention: Saline solution placebo
Number of subjects: 93
Study 3935203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 400
Study 3935203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline and Berberine
Number of subjects: 400
Study 3935203 — intervention group
Group type: COMPARATOR
Intervention: Berberine
Number of subjects: 400
Study 3935203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 31908513 — intervention group
Group type: EXPERIMENTAL
Intervention: Wash+lotion
Number of subjects: 130
Study 31908513 — intervention group
Group type: COMPARATOR
Intervention: Water+lotion
Number of subjects: 130
Study 31908513 — intervention group
Group type: COMPARATOR
Intervention: Water alone
Number of subjects: 130
Study 30152116 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual induction therapy (rATG combined with either daclizumab or alemtuzumab) with planned early corticosteroid withdrawal
Number of subjects: 200
Study 26266654 — intervention group
Group type: EXPERIMENTAL
Intervention: Silorane-based composite light-cured for 80 seconds at 800 mW/cm(2)
Number of subjects: 432
Study 26266654 — intervention group
Group type: COMPARATOR
Intervention: Silorane-based composite
Number of subjects: 432
Study 26266654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both resin composites
Number of subjects: 432
Study 26266654 — intervention group
Group type: COMPARATOR
Intervention: Methacrylate-based composite
Number of subjects: 432
Study 23456215 — intervention group
Group type: EXPERIMENTAL
Intervention: Clown intervention
Number of subjects: 50
Study 23456215 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine procedure)
Number of subjects: 50
Study 21909729 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g/day)
Number of subjects: 83
Study 21909729 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (70 mg/week)
Number of subjects: 83
Study 20638351 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dissonance (CD)
Number of subjects: 106
Study 20638351 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified healthy weight (MHW)
Number of subjects: 106
Study 17185636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine prolonged-release implants (NPRIs)
Number of subjects: 32
Study 17185636 — intervention group
Group type: COMPARATOR
Intervention: Control (no NPRIs)
Number of subjects: 32
Study 15455791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-dialysis clinic intervention
Number of subjects: 2200
Study 11853894 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and relaxation tape
Number of subjects: 243
Study 11853894 — intervention group
Group type: COMPARATOR
Intervention: Music tape of their choice
Number of subjects: 243
Study 9667087 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR) - individualized 30-minute therapy session with head, eye, and body exercises
Number of subjects: 143
Study 9667087 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (control group)
Number of subjects: 143
Study 9228466 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 micrograms 1 alpha(OH)D3/day
Number of subjects: 121
Study 9228466 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50-0.75 micrograms 1 alpha(OH)D3/day
Number of subjects: 121
Study 9228466 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 121
Study 1742754 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg) administered via i.v. infusion starting 30 min before APO administration.
Number of subjects: 12
Study 1742754 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group) administered via i.v. infusion starting 30 min before APO administration.
Number of subjects: 12
Study 7023224 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretylium tosylate
Number of subjects: 146
Study 7023224 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine hydrochloride
Number of subjects: 146
Study 30542933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 15
Study 30542933 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound (SHAM)
Number of subjects: 15
Study 30542933 — intervention group
Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 15
Study 28902040 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg administered twice daily for 12 weeks
Number of subjects: 80
Study 28902040 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rifaximin)
Number of subjects: 80
Study 28902040 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 23622262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cat saliva 9cH and Histaminum 9cH (combined), taken as two tablets twice daily for 4 weeks
Number of subjects: 30
Study 23622262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21489086 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin pretreatment
Number of subjects: 751
Study 21489086 — intervention group
Group type: COMPARATOR
Intervention: Control (non-statin pretreatment)
Number of subjects: 751
Study 19036752 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily lamivudine, tenofovirDF and nevirapine (Group 2)
Number of subjects: 250
Study 19036752 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine/lamivudine and nevirapine twice daily (Group 1)
Number of subjects: 250
Study 17156512 — intervention group
Group type: COMPARATOR
Intervention: Standard pain treatment
Number of subjects: 15
Study 17156512 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 15
Study 17156512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 15
Study 17156512 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro acupuncture
Number of subjects: 15
Study 17156512 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro acupuncture at non-acupuncture points
Number of subjects: 15
Study 15053120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation head movement exercises (slow movement group)
Number of subjects: 53
Study 15053120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation head movement exercises (rapid movement group)
Number of subjects: 53
Study 11291999 — intervention group
Group type: EXPERIMENTAL
Intervention: TYR-free amino acid drink
Number of subjects: 0
Study 11291999 — intervention group
Group type: COMPARATOR
Intervention: BAL amino acid drink
Number of subjects: 0
Study 9223094 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonemic fluency task
Number of subjects: 6
Study 9223094 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic fluency task
Number of subjects: 6
Study 9223094 — intervention group
Group type: COMPARATOR
Intervention: Resting state
Number of subjects: 6
Study 7801588 — intervention group
Group type: EXPERIMENTAL
Intervention: Local administration of metromidasole with dimethysulfoxide
Number of subjects: 669
Study 3003259 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (radiation therapy combined with chemotherapy)
Number of subjects: 80
Study 3003259 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 80
Study 3003259 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 80
Study 31233321 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of stigma
Number of subjects: 516
Study 31233321 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalized stigma
Number of subjects: 516
Study 31233321 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 516
Study 31233321 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 516
Study 31233321 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery orientation
Number of subjects: 516
Study 31233321 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived quality of life
Number of subjects: 516
Study 31233321 — intervention group
Group type: EXPERIMENTAL
Intervention: Social withdrawal
Number of subjects: 516
Study 30156193 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) - single dose immediately after surgery (0.3 W, 40 s, 4 J/cm2)
Number of subjects: 45
Study 30156193 — intervention group
Group type: COMPARATOR
Intervention: Placebo group - sham therapy immediately after surgery
Number of subjects: 45
Study 30156193 — intervention group
Group type: COMPARATOR
Intervention: Control group - routine management (ice application)
Number of subjects: 45
Study 30156193 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (LLLT, placebo, control)
Number of subjects: 45
Study 26458326 — intervention group
Group type: EXPERIMENTAL
Intervention: UCP1 -3826 A>G polymorphism (mutated allele G)
Number of subjects: 150
Study 26458326 — intervention group
Group type: EXPERIMENTAL
Intervention: UCP1 -3826 A>G polymorphism (mutated homozygotes GG)
Number of subjects: 150
Study 24675245 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 360
Study 24675245 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil and chewing gum
Number of subjects: 360
Study 24675245 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 360
Study 24675245 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 360
Study 24675245 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 360
Study 22983407 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial caries removal (PCR)
Number of subjects: 299
Study 22983407 — intervention group
Group type: COMPARATOR
Intervention: Stepwise excavation (SW)
Number of subjects: 299
Study 20236791 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 44
Study 20236791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 18349177 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0
Study 18349177 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid
Number of subjects: 0
Study 18349177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 18349177 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16013662 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 microg kg(‐1) remifentanil + propofol 2 mg kg(‐1)
Number of subjects: 60
Study 16013662 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 microg kg(‐1) remifentanil + propofol 2 mg kg(‐1)
Number of subjects: 60
Study 16013662 — intervention group
Group type: COMPARATOR
Intervention: Normal saline + propofol 2.5 mg kg(‐1)
Number of subjects: 60
Study 12441717 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 609
Study 12441717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study 10514958 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 10514958 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 8745672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (iv) administration of 12 IU/m2/24 hours IL2, continuous infusion from day 5 to day 3 before surgery
Number of subjects: 18
Study 8745672 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (sc) administration of 18 IU IL2, in 2 SC injections per day from day 4 to day 2 before surgery
Number of subjects: 18
Study 1921784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine (10-30 mg)
Number of subjects: 5
Study 1921784 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine (1-3 mg)
Number of subjects: 5
Study 1921784 — intervention group
Group type: COMPARATOR
Intervention: Oral levodopa
Number of subjects: 5
Study 6405444 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg IV naloxone
Number of subjects: 20
Study 6405444 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study 31938829 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic pantoprazole
Number of subjects: 3291
Study 31938829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3291
Study 31261247 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Intervention (EI) group using the IBD Pocket Guide
Number of subjects: 0
Study 31261247 — intervention group
Group type: COMPARATOR
Intervention: Usual Care group
Number of subjects: 0
Study 28976791 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, Cisplatin, and Infusional Fluorouracil (ECF)
Number of subjects: 546
Study 28976791 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil and Leucovorin (FU plus LV)
Number of subjects: 546
Study 27555193 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block (15‐20 mL 0.5% ropivacaine, maximum 3 mg/kg)
Number of subjects: 71
Study 27555193 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 71
Study 27555193 — intervention group
Group type: COMPARATOR
Intervention: Control (20 to 30 mL 0.5% ropivacaine infiltrated preincision)
Number of subjects: 71
Study 27555193 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia fentanyl
Number of subjects: 71
Study 25088940 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 592
Study 25088940 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 592
Study 23130573 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme supplemented diets
Number of subjects: 0
Study 23130573 — intervention group
Group type: COMPARATOR
Intervention: Control diet (corn-soyabean without enzyme supplementation)
Number of subjects: 0
Study 19852288 — intervention group
Group type: EXPERIMENTAL
Intervention: Gulling Pa'an Capsule (GPC) in group A
Number of subjects: 242
Study 19852288 — intervention group
Group type: COMPARATOR
Intervention: Placebo in group B
Number of subjects: 242
Study 19852288 — intervention group
Group type: EXPERIMENTAL
Intervention: Gulling Pa'an Capsule + Levodopa in group C
Number of subjects: 242
Study 19852288 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Levodopa in group D
Number of subjects: 242
Study 19852288 — intervention group
Group type: EXPERIMENTAL
Intervention: Gulling Pa'an Capsule + Levodopa in group E
Number of subjects: 242
Study 19852288 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Levodopa in group F
Number of subjects: 242
Study 19852288 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa dosage in groups C and E
Number of subjects: 242
Study 17501848 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg
Number of subjects: 613
Study 17501848 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 20 mg
Number of subjects: 613
Study 15037889 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost instillation once daily in the morning
Number of subjects: 62
Study 15037889 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol instillation twice daily
Number of subjects: 62
Study 11684631 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal pregnancy (NP)
Number of subjects: 60
Study 11684631 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy-induced hypertension (PIH)
Number of subjects: 60
Study 11684631 — intervention group
Group type: COMPARATOR
Intervention: Normotensive nonpregnant (NN)
Number of subjects: 60
Study 11684631 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum (after delivery)
Number of subjects: 60
Study 9687551 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60 mg of oily solution of retinyl palmitate, 30 mg if aged <12 mo) every 6 mo
Number of subjects: 358
Study 9687551 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg) every 3 mo
Number of subjects: 358
Study 9687551 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 358
Study 9687551 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 358
Study 9687551 — intervention group
Group type: EXPERIMENTAL
Intervention: Deworming
Number of subjects: 358
Study 9687551 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in boys
Number of subjects: 358
Study 9687551 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in girls
Number of subjects: 358
Study 9687551 — intervention group
Group type: EXPERIMENTAL
Intervention: Deworming in boys and girls
Number of subjects: 358
Study 7976148 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation of the epigastrium
Number of subjects: 40
Study 7976148 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation of the right axilla
Number of subjects: 40
Study 7976148 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation of the left axilla
Number of subjects: 40
Study 7976148 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetist's feeling when squeezing the bag
Number of subjects: 40
Study 3141143 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/kg/d for those weighing less than 6 kg and 50 mg daily for those over 6 kg)
Number of subjects: 60
Study 3141143 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 60
Study 3141143 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 60
Study 31898518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD) with a restricted carbohydrate intake of 20-40 g/day
Number of subjects: 111
Study 31898518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting Diet (FD) with a 7-day fast every 6 months and 14-hour daily intermittent fasting
Number of subjects: 111